Association of the HLA-DQA1*05 Allelic Gene Variants with Immunogenicity to Anti-TNF therapeutics—Important Differences Between Infliximab and Adalimumab
Open Access
- 16 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (4)
Abstract
Nicola Ternette, Hanqing Liao, Jack Satsangi; Association of the HLA DQA1*05 allelic gene variants with immunogenicity to anti-TNF therapeutics - importantKeywords
Funding Information
- The Leona M. and Harry B. Helmsley Charitable Trust (G-2307-06213)
This publication has 3 references indexed in Scilit:
- HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn’s Disease StudiesJournal of Crohn's and Colitis, 2024
- Underpowered PANTS: A Response to the Conclusions of “Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab”Gastroenterology, 2021
- Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabGastroenterology, 2020